GlassScriptPhysician profile
April C Lust
NPI 1013996222
$1,864.39
in general payments reported to CMS, 2019-2025
26 companies · $647 in 2025
The $647 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $233 · 2024: $523 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.48 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $243.79 | 2021-2025 | |
| Amgen INC. | $194.45 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $175.54 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $116.17 | 2021-2025 | Bexsero, Arexvy, Trelegy Ellipta |
| Ironshore Pharmaceuticals INC. | $110.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $60.94 | 2021-2022 | |
| Exact Sciences Corporation | $57.87 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $44.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.18 | 2021 | |
| Abbott Laboratories | $43.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $42.94 | 2021 | |
| Collegium Pharmaceutical, INC. | $42.64 | 2025 | Jornay Pm |
| Esperion Therapeutics, INC. | $36.12 | 2021-2022 | |
| Inari Medical, INC. | $35.89 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35.63 | 2021 | |
| Astellas Pharma US INC | $34.16 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.09 | 2021-2022 | |
| Dexcom, INC. | $28.86 | 2021-2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $26.58 | 2025 | Evkeeza |
| Daiichi Sankyo INC. | $25.45 | 2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $23.90 | 2025 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $18.31 | 2022 | |
| Corium, LLC | $15.10 | 2024 | Azstarys |
| Alk-Abello, INC | $14.87 | 2025 | Neffy |
| Mylan Specialty L.P. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Lust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.